The core focus of our R&D and business activities is to help companies enhance current drugs or develop new transdermal and oral dosage products based on the NexACT technology. At NexMed we are always interested in partnerships that will increase the likelihood of success and help improve patient outcomes.
We are also interested in out-licensing our clinical and pre-clinical products for treating onychomycosis, psoriasis, sexual dysfunction and cancer.
To learn more about the NexACT technology and licensing inquiries, please contact:
Mark S. Wilson
MWilson@NEXMED.com
Vice President of Technology Development
NexMed USA, Inc.
858-222-8041 office
To learn more about NexMed’s clinical and preclinical products and licensing inquiries, please contact:
Linda Smibert
LSmibert@NEXMED.com
Vice President of Business Development
NexMed USA, Inc.
858-222-8041 office
For any other questions or comments please contact:
Edward Cox
ECox@NEXMED.com
Vice President of Corporate Development
NexMed, Inc.
858-926-5811 office
